Todd Pettingill
Corporate Officer/Principal chez OMNIAB, INC.
Profil
Todd Pettingill is currently the Vice President of Business Development and Strategy at OmniAb Operations, Inc. and OmniAb, Inc. He previously worked as a Senior Manager of Corporate Development at Ligand Pharmaceuticals, Inc. Mr. Pettingill received his undergraduate degree from Brigham Young University and his MBA from UCLA Anderson School of Management.
Postes actifs de Todd Pettingill
Sociétés | Poste | Début |
---|---|---|
OMNIAB, INC. | Corporate Officer/Principal | - |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Anciens postes connus de Todd Pettingill
Sociétés | Poste | Fin |
---|---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Investor Relations Contact | - |
Formation de Todd Pettingill
Brigham Young University | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
OMNIAB, INC. | Commercial Services |
Entreprise privées | 1 |
---|---|
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |